Estrogen receptor agonists and immune system in ovariectomized mice

International Journal of Immunopathology and Pharmacology

Volumn 19, Issue 4, 2006, Pages 807-819

  García Pérez, Miguel Angel ^a   Del Val, R ^a   Noguera, I ^b   Hermenegildo, C ^a,b   Pinedal, B ^a   Martinez Romero A ^b   Cano, A ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Estradiol; Estrogen deficiency; Genistein; Immune system; Ovariectomy; Raloxifene; T cells

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CATHEPSIN K; ESTRADIOL; GAMMA INTERFERON; GENISTEIN; INTERLEUKIN 6; RALOXIFENE; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; BODY WEIGHT; BONE MARROW CELL; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CD25+ T LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ESTROGEN DEFICIENCY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HYPERTROPHY; IMMUNE SYSTEM; MOUSE; NONHUMAN; OVARIECTOMY; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; THYMUS HYPERTROPHY; UTERINE ATROPHY;

EID: 33846437805     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200601900410     Document Type: Article

References (40)

1. Riggs B.L., S. Khosla and L.J. Melton, III. 1998. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13:763.
2. Rossouw J.E., G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen and J. Ockene. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321.
3. Delmas P.D., N.H. Bjarnason, B.H. Mitlak, A.C. Ravoux, A.S. Shah, W.J. Huster, M. Draper and C. Christiansen. 1997. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337:1641.
4. Cummings S.R., et al. 1999. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189.
5. Dang Z.C. and C. Lowik. 2005. Dose-dependent effects of phytoestrogens on bone. Trends Endocrinol. Metabol. 6:207.
6. Agarwal R. 2000. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem. Pharmacol. 60:1051.
7. Sato T., T. Shibata, K. Ikeda and K. Watanabe. 2001. Generation of bone-resorbing osteoclasts from B220+ cells: its role in accelerated osteoclastogenesis due to estrogen deficiency. J. Bone Miner. Res. 16:2215.
8. Cenci S., M.N. Weitzmann, C. Roggia, N. Namba, D. Novack, J. Woodring and R. Pacifici. 2000. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J. Clin. Invest. 106:1229.
9. Kong Y.Y. et al. 1999. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304.
10. Safadi F.F., LR. Dissanayake, G.G. Goodman, R.A. Jago, A.E. Baker, A.R. Bowman, D.A. Sass, S.N. Popoff and S. Epstein. 2000. Influence of estrogen deficiency and replacement on T-cell populations in rat lymphoid tissues and organs. Endocrine 12:81.
11. Screpanti I., S. Morrone, D. Meco, A. Santoni, A. Gulino, R. Paolini, A. Crisanti, B.J. Mathieson and L. Frati. 1989. Steroid sensitivity of thymocyte subpopulations during intrathymic differentiation. Effects of 17 beta-estradiol and dexamethasone on subsets expressing T cell antigen receptor or IL-2 receptor. J. Immunol. 142:3378.
12. Medina K.L., G. Smithson and P.W. Kincade. 1993. Suppression of B lymphopoiesis during normal pregnancy. J. Exp. Med 178:1507.
13. Medina K.L. and P.W. Kincade. 1994. Pregnancy-related steroids are potential negative regulators of B lymphopoiesis. Proc. Natl. Acad. Sci. U.S.A. 91:5382.
14. Jilka R.L., K. Takahashi, M. Munshi, D.C. Williams, P.K. Roberson and S.C. Manolagas. 1998. Lossof estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J. Clin. Invest. 101:1942.
15. Miyazaki T., T. Matsunaga, S. Miyazaki, S. Hokari and T. Komoda. 2004. Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats, J. Cell Biochem. 93:503.
16. Tanizawa T., A. Yamaguchi, Y. Uchiyama, C. Miyaura, T. Ikeda, S. Ejiri, Y. Nagal, H. Yamato, H. Murayama, M. Sato and T. Nakamura. 2000. Reduction in bone formation and elevated bone resorption in ovariectomized rats with special reference to acute inflammation. Bone 26:43.
17. Weaver C.M., M. Peacock, B.R. Martin, G.P. McCabe, J. Zhao, D.L. Smith and M.E. Wastney. 1997. Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy females. J. Bone Miner. Res. 12:1714.
18. Eghbali-Fatourechi G., S. Khosla, A. Sanyal, W.J. Boyle, D.L. Lacey and B.L. Riggs. 2003. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J. Clin. Invest. 111:1221.
19. Zhou S., Y. Zilberman, K. Wassermann, S.D. Bain, Y. Sadovsky and D. Gazit. 2001. Estrogen modulates estrogen receptor alpha and beta expression, osteogenic activity, and apoptosis in mesenchymal stem cells (MSCs) of osteoporotic mice. J. Cell Biochem. 81:144.
20. Bonnelye E., V. Kung, C. Laplace, D.L. Galson and J.E. Aubin. 2002. Estrogen receptor-related receptor alpha impinges on the estrogen axis in bone: potential function in osteoporosis. Endocrinology 143:3658.
21. Lacey D.L. et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165.
22. Black L.J., M. Sato, E.R. Rowley, D.E. Magee, A. Bekele, D.C. Williams, G.J. Cullinan, R. Bendele. R.F. Kauffman, W.R. Bensch, C.A. Frolik, J.D. Termine and H.U. Bryant. 1994. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J. Clin. Invest 93:63.
23. Erlandsson M.C., C.A. Jonsson, M.K. Lindberg, C. Ohlsson and H. Carlsten. 2002. Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J. Endocrinol. 175:319.
24. Ishimi Y., C. Miyaura, M. Ohmura, Y. Onoe, T. Sato, Y. Uchiyama, M. Ito, X. Wang, T. Suda and S. Ikegami. 1999. Selective effects of genistein, a soybean isoflavone, on B-lymphopoiesis and bone loss caused by estrogen deficiency. Endocrinology 140:1893.
25. Modder U.I., B.L. Riggs, T.C. Spelsberg, D.G. Fraser, E.J. Atkinson, R. Arnold and S. Khosla. 2004. Dose-response of estrogen on bone versus the uterus in ovariectomized mice. Eur. J. Endocrinol. 151:503.
26. Leopold A.S., M. Erwin, J. Oh and B. Browning. 1976. Phytoestrogens: adverse effects on reproduction in California quail. Science 191:98.
27. Masuzawa T., C. Miyaura, Y. Onoe, K. Kusano, H. Ohta, S. Nozawa and T. Suda. 1994. Estrogen deficiency stimulates B lymphopoiesis in mouse bone marrow. J. Clin. Invest. 94:1090.
28. Cumano A., C.J. Paige, N.N. Iscove and G. Brady. 1992. Bipotential precursors of B cells and macrophages in murine fetal liver. Nature 356:612.
29. Kanematsu M., T. Sato, H. Takai, K. Watanabe, K. Ikeda and Y. Yamada. 2000. Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J. Bone Miner. Res. 15:1321.
30. Farrugia A.N., G.J. Atkins, L.B. To, B. Pan, N. Horvath, P. Kostakis, D.M. Findlay, P. Bardy and A.C. Zannettino. 2003. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res. 63:5438.
31. Cenci S., G. Toraldo, M.N. Weitzmann, C. Roggia, Y. Gao, W.P. Qian, O. Sierra and R. Pacifici. 2003. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc. Natl. Acad. Sci. U.S.A. 100:10405.
32. Yang J.H., C.D. Chen, M.Y. Wu, K.H. Chao, Y.S. Yang and H.N. Ho. 2000. Hormone replacement therapy reverses the decrease in natural killer cytotoxicity but does not reverse the decreases in the T-cell subpopulation or interferon-gamma production in postmenopausal women. Fertil. Steril. 74:261.
33. Barr I.G., B.A. Khalid, P. Pearce, B.H. Toh, RF. Bartlett, R.G. Scollay and J.W. Funder. 1982. Dihydrotestosterone and estradiol deplete corticosensitive thymocytes lacking in receptors for these hormones. J. Immunol. 128:2825.
34. Grossman C.J. 1985. Interactions between the gonadal steroids and the immune system. Science 227:257.
35. Erben R.G., G. Hard and H. Graf. 1998. Ovariectomy does not alter CD4+/CD8+ ratio in peripheral blood T-lymphocytes in the rat. Horm. Metab. Res. 30:50.
36. Roggia C., Y. Gao, S. Cenci, M.N. Weitzmann, G. Toraldo, G. Isaia and R. Pacifici. 2001. Upregulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc. Natl. Acad. Sci. U.S.A. 98:13960.
37. Carlsten H., R. Holmdahl, A. Tarkowski and L.A. Nilsson. 1989. Oestradiol suppression of delayed-type hypersensitivity in autoimmune (NZB/NZW)F1 mice is a trait inherited from the healthy NZW parental strain. Immunology 67:205.
38. Hanna N. and M. Schneider. 1983. Enhancement of tumor metastasis and suppression of natural killer cell activity by beta-estradiol treatment. J. Immunol. 130:974.
39. Yu A., F. Olosz, C.Y. Choi and T.R. Malek. 2000. Efficient internalization of IL-2 depends on the distal portion of the cytoplasmic tail of the IL-2R common gamma-chain and a lymphoid cell environment. J. Immunol. 165:2556.
40. Nalbandian G., V. Paharkova-Vatchkova, A. Mao, S. Nale and S. Kovats. 2005. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J. Immunol. 175:2666.